Several eIF4A inhibitors, such as eFT226, silvestrol, hippuristanol, and pateamine A, have demonstrated promising anti-tumor activities in various cancer types conducted in vitro and in vivo studies (Boussemart et al., 2014; Malka-Mahieu et al., 2017; Pelletier et al., 2015). Here, EIF4A1 is linked to cancer.